EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease - PubMed (original) (raw)

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

European Association for the Study of the Liver (EASL) et al. Diabetologia. 2016 Jun.

No abstract available

PubMed Disclaimer

Comment in

• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?
  Bugianesi E. Bugianesi E. Diabetologia. 2016 Jun;59(6):1145-7. doi: 10.1007/s00125-016-3930-7. Epub 2016 Apr 7. Diabetologia. 2016. PMID: 27053231 No abstract available.
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
  Byrne CD, Targher G. Byrne CD, et al. Diabetologia. 2016 Jun;59(6):1141-4. doi: 10.1007/s00125-016-3910-y. Epub 2016 Apr 7. Diabetologia. 2016. PMID: 27053232
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects.
  Toplak H, Stauber R, Sourij H. Toplak H, et al. Diabetologia. 2016 Jun;59(6):1148-9. doi: 10.1007/s00125-016-3941-4. Epub 2016 Apr 7. Diabetologia. 2016. PMID: 27053233 Free PMC article. No abstract available.

Similar articles

• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
  Byrne CD, Targher G. Byrne CD, et al. Diabetologia. 2016 Jun;59(6):1141-4. doi: 10.1007/s00125-016-3910-y. Epub 2016 Apr 7. Diabetologia. 2016. PMID: 27053232
• EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
  Blond E, Disse E, Cuerq C, Drai J, Valette PJ, Laville M, Thivolet C, Simon C, Caussy C. Blond E, et al. Diabetologia. 2017 Jul;60(7):1218-1222. doi: 10.1007/s00125-017-4264-9. Epub 2017 Mar 28. Diabetologia. 2017. PMID: 28352941
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
  European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). European Association for the Study of the Liver (EASL), et al. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. J Hepatol. 2016. PMID: 27062661 No abstract available.
• Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
  Sun X, Zhang Y, Xie M. Sun X, et al. Acta Pharm. 2017 Mar 1;67(1):1-13. doi: 10.1515/acph-2017-0007. Acta Pharm. 2017. PMID: 28231052 Review.
• Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.
  Musso G, Cassader M, Gambino R. Musso G, et al. Nat Rev Drug Discov. 2016 Apr;15(4):249-74. doi: 10.1038/nrd.2015.3. Epub 2016 Jan 22. Nat Rev Drug Discov. 2016. PMID: 26794269 Review.

Cited by

• Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.
  Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC. Del Prato S, et al. Cardiovasc Diabetol. 2024 Sep 28;23(1):352. doi: 10.1186/s12933-024-02432-7. Cardiovasc Diabetol. 2024. PMID: 39342203 Free PMC article. Clinical Trial.
• Serum folate levels and risk of metabolic dysfunction-associated steatotic liver disease: results from a cross-sectional study and Mendelian randomization analysis.
  Chen Y, Gao J, Wang X, Lu H, Zheng Y, Ren Q. Chen Y, et al. Front Nutr. 2024 Sep 4;11:1437183. doi: 10.3389/fnut.2024.1437183. eCollection 2024. Front Nutr. 2024. PMID: 39296498 Free PMC article.
• Strategy for treating MAFLD: Electroacupuncture alleviates hepatic steatosis and fibrosis by enhancing AMPK mediated glycolipid metabolism and autophagy in T2DM rats.
  Duan H, Song S, Li R, Hu S, Zhuang S, Liu S, Li X, Gao W. Duan H, et al. Diabetol Metab Syndr. 2024 Sep 11;16(1):218. doi: 10.1186/s13098-024-01432-7. Diabetol Metab Syndr. 2024. PMID: 39261952 Free PMC article.
• METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE - ASSESSMENT OF PATIENTS WITH OBESITY AND METABOLIC SYNDROME - GUIDELINE FROM THE BRAZILIAN SOCIETY OF BARIATRIC AND METABOLIC SURGERY.
  Halamy Pereira L, Barros F, Andrade TG, Oliveira Neto AA, Nogueira CAV, Valezi AC. Halamy Pereira L, et al. Arq Bras Cir Dig. 2024 Sep 2;37:e1821. doi: 10.1590/0102-6720202400028e1821. eCollection 2024. Arq Bras Cir Dig. 2024. PMID: 39230102 Free PMC article.
• Establishment and Evaluation of a Noninvasive Metabolism-Related Fatty Liver Screening and Dynamic Monitoring Model: Cross-Sectional Study.
  Ni J, Huang Y, Xiang Q, Zheng Q, Xu X, Qin Z, Sheng G, Li L. Ni J, et al. Interact J Med Res. 2024 Aug 22;13:e56035. doi: 10.2196/56035. Interact J Med Res. 2024. PMID: 39172506 Free PMC article.

References

1. 1. N Engl J Med. 2010 Sep 30;363(14 ):1341-50 - PubMed
2. 1. PLoS Med. 2014 Jul 22;11(7):e1001680 - PubMed
3. 1. Liver Int. 2014 Jan;34(1):129-35 - PubMed
4. 1. J Hepatol. 2012 Aug;57(2):384-91 - PubMed
5. 1. Diabetes. 2004 Aug;53(8):2169-76 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information